Core Viewpoint - The company, Sichuang Medical Technology Co., Ltd., has undergone significant leadership changes, with the resignation of Chairman Xu Yiran and the appointment of Wei Naixu as the new chairman and legal representative, indicating a restructuring effort within the company's governance [1][2]. Leadership Changes - Xu Yiran resigned from his positions as Chairman, Strategic Decision Committee Chair, and Audit Committee member to facilitate governance optimization, while remaining a board member [1]. - Wei Naixu was elected as the new Chairman and legal representative of the company, with his term starting from the approval date of the board meeting [1]. - Wu Weibin was appointed as the new Deputy General Manager, with his term also starting from the same board meeting [1]. Shareholding and Control - Wei Naixu indirectly holds 20,732,440 shares (1.85% of total shares) through Cangnan Xinchuan and has control over 63,890,185 shares (5.72%) via Cangnan Xincheng, making him the actual controller of the company with a total of 83,471,940 shares (7.47%) after a pending share transfer [2]. - After the share transfer is completed, Wei Naixu will control a total of 147,362,125 shares (13.18% of total shares) [2]. Company Background - Sichuang Medical Technology Co., Ltd. was established in 2003 and listed on the Shenzhen Stock Exchange in April 2010, recognized as a leading provider of smart medical and IoT application solutions [5]. Financial Performance - The company has faced significant financial challenges, reporting continuous net profit losses over the past five years, with cumulative losses exceeding 3 billion yuan [6]. - In the latest financial report, the company achieved a revenue of 603.8 million yuan in the first three quarters, a year-on-year increase of 6.95%, but still reported a net loss of 4.762 million yuan [6].

格隆汇12月3日丨思创医惠（维权）(300078.SZ)公布，董事会于近日收到董事长许益冉先生的书面辞职 报告，许益冉先生为配合公司治理结构优化调整申请辞去第六届董事会董事长、战略决策委员会主任委 员（召集人）以及审计委员会成员职务，并不再担任公司法定代表人，辞职后许益冉先生仍继续担任公 司第六届董事会董事。上述职务原定任期为2024年12月6日至2027年12月5日。 鉴于公司原董事长已辞去董事长职务，并不再担任公司法定代表人，为保证董事会规范运作，公司于 2025年12月3日召开第六届董事会第十四次会议，审议通过了《关于选举第六届董事会董事长、代表公 司执行公司事务的董事的议案》，董事会全体董事一致同意选举魏乃绪先生为公司第六届董事会董事 长、代表公司执行公司事务的董事，任期自第六届董事会第十四次会议审议通过之日起至第六届董事会 任期届满之日止。 ...

北京商报讯（记者 丁宁）12月3日晚间，思创医惠（300078）发布公告称，公司董事会于近日收到董事 长许益冉的书面辞职报告，许益冉为配合公司治理结构优化调整申请辞去第六届董事会董事长、战略决 策委员会主任委员（召集人）以及审计委员会成员职务，并不再担任公司法定代表人，辞职后许益冉仍 继续担任公司第六届董事会董事。 资料显示，魏乃绪1981年出生，现任浙江码尚科技股份有限公司董事长。2024年12月至今，任公司董 事、总经理。 为进一步完善公司治理结构，保障公司各专门委员会能够顺利高效开展工作，充分发挥各位委员的专业 特长，董事会结合公司实际情况对第六届董事会专门委员会部分成员进行调整，公司于12月3日召开第 六届董事会第十四次会议，审议通过了《关于调整第六届董事会专门委员会成员的议案》，选举魏乃绪 为第六届董事会战略决策委员会主任委员（召集人），选举何毅琦为第六届董事会审计委员会成员，将 第六届董事会薪酬与考核委员会委员叶肖剑调整为何毅琦。 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-118 思创医惠科技股份有限公司 关于董事长辞职及补选董事长、变更法定代表人、调整专门 委员会成员暨聘任副总经理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 事务的董事担任"，因此代表公司执行公司事务的董事魏乃绪先生将担任公司法 定代表人。公司管理层将尽快按照法定程序完成法定代表人变更的相关工商变更 登记事宜。 三、关于调整专门委员会成员的情况 一、关于董事长辞职的情况 思创医惠科技股份有限公司（以下简称"公司"）董事会于近日收到董事长 许益冉先生的书面辞职报告，许益冉先生为配合公司治理结构优化调整申请辞去 第六届董事会董事长、战略决策委员会主任委员（召集人）以及审计委员会成员 职务，并不再担任公司法定代表人，辞职后许益冉先生仍继续担任公司第六届董 事会董事。上述职务原定任期为 2024 年 12 月 6 日至 2027 年 12 月 5 日。 根据《中华人民共和国公司法》（以下简称"《公司法》"）及《公司章程》 等有关规定，许益冉先生的辞职报告自送达董事会之日起生效。许益冉先生作为 公 ...

北京天元（杭州）律师事务所 关于思创医惠科技股份有限公司 2025 年第六次临时股东会的法律意见 京天股字（2025）第 730 号 致：思创医惠科技股份有限公司 思创医惠科技股份有限公司（以下简称"公司"）2025 年第六次临时股东会（以 下简称"本次股东会"）采取现场表决与网络投票相结合的方式，现场会议于 2025 年 12 月 3 日（星期三）下午 14:30 在公司会议室（浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室）召开。北京天元（杭州）律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师参加本次股东会现场会议，并根据《中华人民 共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股东会规则》（以下简称"《股东会规则》"）以及《思创医惠科技股份有限 公司章程》（以下简称"《公司章程》"）等有关规定，就本次股东会的召集、召开 程序、出席现场会议人员的资格、召集人资格、会议表决程序及表决结果等事项出 具本法律意见。 为出具本法律意见，本所律师审查了《思创医惠科技股份有限公司第六届董 事会第十三次会议决议公告》、《思创医惠科技股份有限公司关于召开 202 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-116 思创医惠科技股份有限公司 2025 年第六次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 6、会议主持人：公司董事长魏乃绪先生 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025 年 12 月 3 日（星期三）14:30 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 3 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 3 日 9:15 至 15:00 期间的任意时间。 3、现场会议召开地点：浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室 4、会议召开方式：本次股东会采取现场投票表决和网络投票表决相结合的 方式 5、会议召集人：公司董事会 7、会议召开的合法、合规性：本次股东会的召集、召开及表决程序符合《中 华人 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-117 思创医惠科技股份有限公司 第六届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 一、董事会会议召开情况 思创医惠科技股份有限公司（以下简称"公司"）第六届董事会第十四次会 议于 2025 年 12 月 3 日在浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼 会议室以现场表决和通讯表决相结合的方式召开。会议通知于 2025 年 11 月 28 日通过电子邮件、电话方式送达各位董事。本次会议应出席董事 8 人，实际出席 董事 8 人。因公司董事许益冉先生已向董事会辞去董事长职务，经董事会过半数 的董事共同推举，本次会议由董事魏乃绪先生召集并主持，公司高级管理人员列 席了会议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律法规和《公司章程》的规定。 （3）将第六届董事会薪酬与考核委员会委员叶肖剑先生调整为何毅琦先生。 1、审议通过了《关于选举第六届董事会董事长、代表公司执行公司事务的 董事 ...

Core Insights - The DRG/DIP concept sector experienced a decline of 0.89%, ranking among the top losers in the market [1] - Notable stocks within the sector included Langchao Software, Jiayuan Technology, and Digital Certification, which saw significant declines, while Shichuang Medical, Taiji Co., and Saili Medical were among the few that increased in value [1] Market Performance - The top-performing concept sectors included Smart Speakers (+3.71%), AI Phones (+3.39%), and Zinc Metals (+2.86%), while the DRG/DIP sector was among the laggards with a decline of 0.89% [2] - The DRG/DIP sector faced a net outflow of 311 million yuan, with 17 stocks experiencing net outflows, and 9 stocks seeing outflows exceeding 10 million yuan [2] Key Stocks and Fund Flow - Langchao Software led the outflow with a net withdrawal of 148 million yuan, followed by Rongke Technology and Shichuang Medical with outflows of 53.22 million yuan and 32.94 million yuan, respectively [2][3] - Conversely, Taiji Co., Weining Health, and Guoxin Health were the top gainers in terms of net inflow, attracting 41.91 million yuan, 16.34 million yuan, and 7.48 million yuan, respectively [2] Detailed Stock Movements - Langchao Software saw a decline of 6.01% with a turnover rate of 22.29% and a net outflow of 147.51 million yuan [2][3] - Other notable declines included Rongke Technology (-2.50%), Shichuang Medical (+4.18%), and Donghua Software (-0.20%) [2][3] - Taiji Co. and Weining Health showed positive movements with increases of 1.60% and 1.28%, respectively, while Guoxin Health remained stable with a slight decrease of 0.20% [2][3]

Group 1 - The core viewpoint of the news is that 思创医惠's stock has experienced fluctuations, with a recent decline of 2.20% and a total market value of 4.45 yuan per share, amounting to 49.75 billion yuan [1] - The company has seen a year-to-date stock price increase of 46.38%, but a recent decline of 8.81% over the last five trading days [1] - The company has been listed on the龙虎榜 five times this year, with the most recent occurrence on November 19 [1] Group 2 - As of September 30, the number of shareholders for 思创医惠 is 58,400, a decrease of 11.34% from the previous period [2] - For the period from January to September 2025, the company achieved a revenue of 604 million yuan, representing a year-on-year growth of 6.95% [2] - The company reported a net profit attributable to shareholders of -4.76 million yuan, showing a year-on-year increase of 98.32% [2] Group 3 - Since its A-share listing, 思创医惠 has distributed a total of 532 million yuan in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - The stock price of Sichuang Medical has increased significantly this year, with a notable rise in recent trading days, indicating strong market interest and potential growth in the healthcare technology sector [2]. Group 1: Stock Performance - Sichuang Medical's stock price has risen by 54.61% year-to-date, with a 4.21% increase in the last five trading days, a 32.02% increase over the last 20 days, and a 27.37% increase over the last 60 days [2]. - The company has appeared on the stock market's "Dragon and Tiger List" five times this year, with the most recent appearance on November 19 [2]. Group 2: Company Overview - Sichuang Medical, established on November 21, 2003, and listed on April 30, 2010, is based in Hangzhou, Zhejiang Province, and focuses on smart hospital solutions, disease research management, and AI services in healthcare [2]. - The company's revenue composition includes 53.84% from real estate sales, 39.28% from business intelligence, and 6.87% from smart healthcare [2]. - Sichuang Medical is classified under the computer-IT services industry and is associated with various concepts such as DRG, family doctor, and new retail [2]. Group 3: Financial Performance - For the period from January to September 2025, Sichuang Medical reported a revenue of 604 million yuan, reflecting a year-on-year growth of 6.95%, while the net profit attributable to shareholders was -4.76 million yuan, showing a significant year-on-year improvement of 98.32% [2]. - As of September 30, the number of shareholders was 58,400, a decrease of 11.34% from the previous period, while the average circulating shares per person increased by 12.79% to 19,077 shares [2]. Group 4: Dividend Information - Since its A-share listing, Sichuang Medical has distributed a total of 532 million yuan in dividends, with no dividends paid in the last three years [3].